---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-017458"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2025-02-11T23:59:59+00:00"
generated_at: "2026-05-26T23:12:54.107890+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics appoints Robert E. Landry to Board of Directors, effective Feb 10, 2025

## Summary
- Robert E. Landry appointed as Class II director, term expiring at 2027 annual meeting.
- Also appointed to Audit Committee; Board determined independent under SEC and Nasdaq rules.
- Compensation includes $50k annual retainer, $12.5k Audit Committee retainer, and annual equity grant of $440k.
- Received initial option grant of 25,538 shares with $700k grant date fair value, vesting over three years.
- Standard indemnification agreement entered into; no other arrangements or transactions requiring disclosure.

## SEC filing metadata
- accession: 0000950170-25-017458
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2025-02-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017025017458/0000950170-25-017458-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017025017458/cytk-20250210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-017458
- JSON: https://secwatch.observer/filing/0000950170-25-017458.json
- Plain text: https://secwatch.observer/filing/0000950170-25-017458.txt

## Source-grounded claims
- claim_id: 2a7ffe8f79
  claim: Robert E. Landry was appointed as Director at CYTOKINETICS INC.
  evidence_excerpt: On February 10, 2025, (the “ Effective Date ”), the Board of Directors (the “ Board ”) of Cytokinetics, Incorporated (the “ Company ”) appointed, upon the recommendation of the Nominating and Governance Committee of the Board, Robert E. Landry to fill a vacant Board seat and to serve as a Class II member of the Board with an initial term expiring at the Company’s 2027 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061983/000095017025017458/0000950170-25-017458-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.